Welcome to the
Does Hay Fever spoil your summer?
The ARIAS Study is a clinical research study, which is looking to assess the effect of an investigational drug, IRL201104, on the allergic response in subjects who are known to be allergic to grass pollen.
We are currently recruiting adults aged 18-65 with a clinical history of grass polleninduced allergic rhinitis for at least 2 years with peak symptoms in May, June, or July.
This is a Phase 2a randomised, double-blind, placebo-controlled, parallel-design, allergen challenge 12-week study of IRL201104 versus placebo in adult participants with seasonal allergic rhinitis.
This trial may provide evidence to support the mechanism of action, the dose and the duration of dosing of IRL201104. This information may be implemented subsequently in a larger trial under natural allergen exposure conditions.
Allergies happen when your immune system overreacts to a substance (an allergen such as grass pollen) that would otherwise be harmless. Hay fever, also called allergic rhinitis, affects around 25% of the UK and European population. Its symptoms generally include itchy, runny or stuffy nose and sneezing, and it can have a major impact on quality of life.
Current treatment for seasonal grass allergy includes taking over the counter or prescription medications to help reduce the symptoms, although they do not eliminate the allergy.
Before enrolling in the study, participants will be provided detailed information about all study visits and related tests and procedures.
Eligible participants will be randomized in a 1:1 ratio (IRL201104: placebo) on Day 1 and will enter the double-blind treatment period.
Participants will be randomized to receive blinded IRL201104, 8 mg will be given by an intravenous injection or matching placebo treatment on Day 1 and thereafter once every 2 weeks for 10 weeks (6 total doses in the treatment period). Participants will return at Week 12 for the final study visit.
If you are eligible to participate in the study, you will receive compensation for your travel expenses.
The total study length is 12 weeks. The study visits are summarized below:
Visits every 2 weeks to provide treatment and monitor your general health and hay fever symptoms
The ARIAS clinical study is led by Professor Stephen Till.
The study will be conducted in:
1. Clinical Research Facility, Guy’s Hospital, Great Maze Pond, London, SE1 9RT, and
2. Hammersmith Medicines Research (HMR), 44 Cumberland Avenue, London NW10 7EW
Am I eligible?
Thank you for your interest in joining the ARIAS Study, please register by completing the below form.